English
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
slide1

Antibody Screening using Phage Display Technology: Protocol and FAQs

Learn about Antibody Screening protocol using Phage Display Technology

Request Quote
01

Background

Antibody is an indispensable core tool in modern Biopharmaceutical development. Its applications include Immunodiagnostic Reagent Development, Anti-tumor Therapy, and Drug Target Discovery and Validation. Traditional Hybridoma Technology faces limitations like long development cycles, difficult humanization, and narrow target selection. Phage Display Technology effectively addresses these issues. The core principle of Phage Display directly couples the Antibody Gene with the Expressed Protein on the phage surface[1]. The Genotype and Phenotype were connected successfully. This enables Affinity Screening for Antibody Development. Antibodies produced this way offer high humanization potential and ease of modification. These advantages provide a solid foundation for subsequent Functional Analysis and Validation. The following section details the entire Phage Antibody Discovery Process.

Phage Antibody Discovery

Phage Display Libraries

The goal of Phage Antibody Discovery is to identify High-Specificity and High-Affinity antibodies against a specific antigen. To achieve antibody gene diversity, three strategies are commonly used to build Phage Display Libraries:
 

Naive Library

Total RNA is extracted from B cells of non-immunized healthy animals (or humans). Reverse transcription produces cDNA. PCR amplification then yields the full repertoire of naturally occurring antibody variable region genes (VH and VL fragments). Finally, genetic engineering randomly assembles VH and VL fragments into scFv or Fab format genes.
 

Synthetic Library

Antibody variable region gene sequences are directly synthesized using Artificial Gene Synthesis technology. 
Naive and Synthetic Library-KMD Bioscience
Fig 1 Naive and Synthetic Library[2]

Immune Library

An animal is immunized to activate B cells producing antigen-specific antibodies. Following are RNA extraction, reverse transcription, and PCR amplification. Ultimately, diverse variable region genes of antibodies that can specifically bind to antigens are obtained. 

Construction of Phage Display Libraries

Following any strategy, the obtained antibody variable region genes (scFv or Fab) are assembled and cloned into vectors. This step creates a Diverse Library of Antibody Fragment Genes. The Antibody Fragment Gene Library is then cloned into a phage display vector (systems like M13, T7, or T4 can be chosen). These genes are expressed with the gene encoding the coat protein pIII. The vector is transformed into competent bacteria. Helper Phage then infect these bacteria. Expression occurs in a Prokaryotic System, producing antibody-pIII fusion proteins. Successful display of antibody fragments on Recombinant Phage surfaces marks the completion of the Phage Display Library. 

Affinity Screening for Target Antibodies

Library Screening uses Biopanning. First, we conjugate the antigen to a solid support, like magnetic beads or a microtiter plate well, to create the immobilized antigen target. The Phage Display Library is then incubated with this immobilized antigen. This step allows specific phage displaying target-binding antibodies (or fragments) to bind. Non-binding Phage are thoroughly washed away using buffers to remove background. Target Phage bound to the antigen are subsequently eluted, which disrupts the antibody-antigen interaction[3]. Alternatively, an excess of soluble competitive antigen can be used for gentler elution. The Eluted Phage Pool then infects a culture of log-phase E. coli for amplification, producing more phage for the next round. This cycle of Binding, Washing, Eluting, and Amplifying is repeated. After 3 to 5 rounds of this stringent selection process, High-Affinity clones recognizing the target antigen are significantly enriched over lower-affinity binders. Finally, individual clones are isolated and characterized to identify leads.

 Phage Display Library's Construction and Biopanning-KMD Bioscience
Fig 2 Phage Display Library’s Construction and Biopanning[2]

Functional and Binding Characterization

After affinity screening, Monoclonal Phage Supernatants undergo ELISA Screening. The purpose is to confirm Antigen-Antibody Binding Activity. Phagemid DNA from Positive Clones is extracted. The antibody genes are subcloned into Expression Vectors. Note: Soluble scFv/Fab expression typically uses Prokaryotic Systems. Full-length IgG expression uses Eukaryotic Systems. Expressed Recombinant Antibodies are purified via affinity chromatography (e.g., using a His-Tag). The purified products require further Validation:
 

Binding Specificity

ELISA and Flow Cytometry (FC) assess specificity for the antigen.
 

Structural Integrity

SDS-PAGE and Western Blot (WB) analyze molecular weight and purity.
 

Affinity Assessment

EC50 values give an initial functional activity readout. Precise dissociation constant (KD) measurement uses Surface Plasmon Resonance (SPR) when needed. 

Summary and Outlook

Phage Display is an in vitro Antibody Screening Technique. It utilizes affinity adsorption on the phage surface. This allows recognition of specific proteins or peptide chains for Screening. The technology provides an efficient platform for Antibody Development.
 

The Screening process involves Key Steps:

(i) Binding
(ii) Washing
(iii) Elution

Its major advantage is significantly shortening discovery timelines. This makes Phage Display ideal for Therapeutic Antibody Generation.
 
    Alpha Lifetech possesses an advanced Phage Display platform. We offer Customizable, High-Quality Phage Display Library Construction services. Our capabilities include building diverse Naive, Immune, Synthetic, and Semi-synthetic Libraries. We then provide professional Biopanning and Antibody Screening services. Ultimately, this enables rapid acquisition of High-Specificity and High-Affinity target antibodies or ligands against specific targets.

    FAQ

    • 1. What is Phage Display Technology? What is its core principle?

    • 2. What are the advantages of phage display over traditional hybridoma technology?

    • 3. What types of antibody libraries does your Phage Display platform offer?

    • 4. How do you ensure the antibodies obtained after screening have high specificity and affinity?

    • 5. Can phage display technology be used if I have post-immunization serum or B cells from animals (e.g., mice, rabbits)?

    • 6. What are the key technical points for constructing a high-quality phage display antibody library?

    • 7. How is the quality of a phage display antibody library assessed?

    • 8. What are the key steps in the Phage Display Library Screening workflow?

      Phage Display Library Screening typically involves 3-4 rounds of Biopanning followed by high-throughput screening (HTS).

      Each panning round includes:
      (i) Binding: Incubating the phage library with immobilized target antigen (e.g., coated wells, magnetic beads) or solution-phase antigen (e.g., biotinylated antigen and streptavidin beads).
      (ii) Washing: Removing unbound/weakly bound phage particles with buffer; washing stringency increases progressively per round.
      (iii) Elution: Recovering specifically bound phage using methods like acidic buffer (e.g., Glycine-HCl), competitive antigen, or protease cleavage.
      (iv) Amplification: Infecting E. coli with eluted phage for amplification to produce the progeny phage pool.

      After Biopanning, we employ HTS technologies including ELISA, Western Blot (WB), Immunofluorescence (IF), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunoprecipitation (IP), Chromatin Immunoprecipitation (ChIP), Peptide Arrays, Flow Cytometry (FC), and gene knockout cell lines. This verifies antibody specificity, reproducibility, stability, and affinity, ensuring the antibodies we produce meet client requirements.

    reference

    [1] Rackaityte E, Proekt I, Miller H S, et al. Validation of a murine proteome-wide phage display library for the identification of autoantibody specificities[J]. bioRxiv, 2023.

    [2] Zhang Y. Evolution of phage display libraries for therapeutic antibody discovery[J]. mAbs, 2023, 15(1):18.

    [3] Lee H E, Cho A H, Hwang J H, et al. Development, High-Throughput Profiling, and Biopanning of a Large Phage Display Single-Domain Antibody Library[J]. International Journal of Molecular Sciences, 2024, 25(9):18.

    [4] Polina V I, Andrey A G, Chatchanok P, et al. Phage display for discovery of anticancer antibodies[J]. New Biotechnology, Volume 83, 2024, Pages 205-218.

    [5] Sakiya K, Yoichi K, Tomoyuki I, et al. Discovery and affinity maturation of antibody fragments from an unfavorably enriched phage display selection by deep sequencing and machine learning[J]. Journal of Bioscience and Bioengineering, Volume 140, Issue 2, 2025, Pages 51-58.